Evidence map›Paper›PMID 39659154›Full record

ArticleJournal of inherited metabolic disease2025

Integration of multi-omics layers empowers precision diagnosis through unveiling pathogenic mechanisms on maple syrup urine disease.

Juan Ramón Tejedor, Alejandro Soriano-Sexto, Leonardo Beccari, Natalia Castejón-Fernández, Patricia Correcher, Lidia Sainz-Ledo, Juan José Alba-Linares, Rocío G Urdinguio, Magdalena Ugarte, Agustín F Fernández and 3 more

Abstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Illuminating diabetesWorld journal of diabetes · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juan Ramón TejedorNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Alejandro Soriano-SextoCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.ORCID 0000-0001-8294-7166
Leonardo BeccariCentre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.
Natalia Castejón-FernándezCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.
Patricia CorrecherNutrition and Metabolopathologies Unit, La Fe University Hospital, Valencia, Spain.
Lidia Sainz-LedoNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Juan José Alba-LinaresNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Rocío G UrdinguioNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Magdalena UgarteCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.
Agustín F FernándezNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Pilar Rodríguez-PomboCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.
Mario F FragaNanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.
Belén PérezCentre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.ORCID 0000-0002-3190-1958

Funding

Asturias Government, Plan de Ciencia Tecnología e Innovación (PCTI) IDI/2021/077European Regional Development FundHealth Research Institute Carlos III (ISCIII) PI21/01067Health Research Institute Carlos III (ISCIII) PI22/00699Ministerio de Ciencia, Innovación y Universidades 501100004837
6 · The paper itself

Abstract

Maple syrup urine disease (MSUD) is a rare inherited metabolic disorder characterized by deficient activity of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex, required to metabolize the amino acids leucine, isoleucine, and valine. Despite its profound metabolic implications, the molecular alterations underlying this metabolic impairment had not yet been completely elucidated. We performed a comprehensive multi-omics integration analysis, including genomic, epigenomic, and transcriptomic data from fibroblasts derived from a cohort of MSUD patients and unaffected controls to genetically characterize an MSUD case and to unravel the MSUD pathophysiology. MSUD patients exhibit a defined episignature that reshapes the global DNA methylation landscape, resulting in the stimulation of HOX cluster genes and the restriction of cell cycle gene-related signatures. Subsequent data integration revealed the impact of AP1-related and CEBPB transcription factors on the observed molecular reorganization, with MEIS1 emerging as a potential downstream candidate affected by robust epigenetic repression in MSUD patients. Furthermore, the integration of multi-omics layers facilitated the identification of a strong epigenetic repression in the DBT promoter in a patient wherein no BCKDH pathogenic variants had been detected. A Circular Chromatin Conformation Capture assay indicated a disturbance of the interactions of DBT promoter, thereby unveiling alternative modes of disease inheritance. Integration of multi-omics data unveiled underlying molecular networks rewired in MSUD patients and represents a powerful approach with diagnostic potential for rare genetic disorders with unknown genetic bases.

Indexed as

DNA MethylationMaple Syrup Urine Disease3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)CCAAT-Enhancer-Binding Protein-betaEpigenesis, GeneticEpigenomicsFemaleFibroblastsGenomicsHumansMaleMultiomicsMyeloid Ecotropic Viral Integration Site 1 ProteinPrecision MedicinePromoter Regions, Genetic3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)CCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanMyeloid Ecotropic Viral Integration Site 1 Proteindata integrationepigenomicsmaple syrup urine diseasemolecular diagnosticstranscriptomics

Identifiers

PMID39659154
PMCPMC11670297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.